QUIDELORTHO CORP (QDEL) Stock Price, Forecast & Analysis

NASDAQ:QDEL • US2197981051

23.735 USD
-5.07 (-17.59%)
At close: Feb 12, 2026
23.3 USD
-0.43 (-1.83%)
After Hours: 2/12/2026, 8:11:32 PM

QDEL Key Statistics, Chart & Performance

Key Statistics
Market Cap1.61B
Revenue(TTM)N/A
Net Income(TTM)-1.18B
Shares67.93M
Float66.77M
52 Week High42.5
52 Week Low19.5
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)2.12
PE11.2
Fwd PE9.36
Earnings (Next)05-05
IPO1991-02-01
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
QDEL short term performance overview.The bars show the price performance of QDEL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20 -30

QDEL long term performance overview.The bars show the price performance of QDEL in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of QDEL is 23.735 USD. In the past month the price decreased by -30.88%. In the past year, price decreased by -41.5%.

QUIDELORTHO CORP / QDEL Daily stock chart

QDEL Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
QDEL Full Technical Analysis Report

QDEL Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to QDEL. QDEL may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
QDEL Full Fundamental Analysis Report

QDEL Financial Highlights

Over the last trailing twelve months QDEL reported a non-GAAP Earnings per Share(EPS) of 2.12. The EPS increased by 14.59% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -20.78%
ROE -57.9%
Debt/Equity 1.23
Chartmill High Growth Momentum
EPS Q2Q%-26.98%
Sales Q2Q%2.23%
EPS 1Y (TTM)14.59%
Revenue 1Y (TTM)N/A
QDEL financials

QDEL Forecast & Estimates

14 analysts have analysed QDEL and the average price target is 38.18 USD. This implies a price increase of 60.85% is expected in the next year compared to the current price of 23.735.

For the next year, analysts expect an EPS growth of 19.63% and a revenue growth 2.28% for QDEL


Analysts
Analysts74.29
Price Target38.18 (60.86%)
EPS Next Y19.63%
Revenue Next Year2.28%
QDEL Analyst EstimatesQDEL Analyst Ratings

QDEL Ownership

Ownership
Inst Owners123.47%
Ins Owners0.61%
Short Float %15.76%
Short Ratio10.7
QDEL Ownership

QDEL Latest News, Press Relases and Analysis

All QDEL news

QDEL Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.41193.832B
ISRG INTUITIVE SURGICAL INC46.82169.664B
SYK STRYKER CORP24.2139.908B
BSX BOSTON SCIENTIFIC CORP21.16109.921B
BDX BECTON DICKINSON AND CO11.2850.66B
IDXX IDEXX LABORATORIES INC41.6649.283B
EW EDWARDS LIFESCIENCES CORP25.7144.358B
RMD RESMED INC20.0135.869B
GEHC GE HEALTHCARE TECHNOLOGY15.6635.845B
DXCM DEXCOM INC25.7825.383B

About QDEL

Company Profile

QDEL logo image QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California and currently employs 6,600 full-time employees. The firm specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. The company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.

Company Info

QUIDELORTHO CORP

9975 Summers Ridge Road

San Diego CALIFORNIA 92121 US

CEO: Douglas C. Bryant

Employees: 6600

QDEL Company Website

QDEL Investor Relations

Phone: 18887057274

QUIDELORTHO CORP / QDEL FAQ

Can you describe the business of QUIDELORTHO CORP?

QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California and currently employs 6,600 full-time employees. The firm specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. The company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.


What is the current price of QDEL stock?

The current stock price of QDEL is 23.735 USD. The price decreased by -17.59% in the last trading session.


Does QDEL stock pay dividends?

QDEL does not pay a dividend.


What is the ChartMill rating of QUIDELORTHO CORP stock?

QDEL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Is QUIDELORTHO CORP (QDEL) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on QDEL.


What is the market capitalization of QDEL stock?

QUIDELORTHO CORP (QDEL) has a market capitalization of 1.61B USD. This makes QDEL a Small Cap stock.


What is the next earnings date for QDEL stock?

QUIDELORTHO CORP (QDEL) will report earnings on 2026-05-05.